伊立替康联合洛铂治疗复发广泛期小细胞肺癌临床观察
 |
| 第1页 |
参见附件(1949KB，2页)。
【摘要】 目的 观察伊立替康联合洛铂治疗复发的广泛期小细胞肺癌(SCLC)的疗效及毒副反应。方法 选取2007年8月至2010年8月在福建省肿瘤医院住院的复发广泛期小细胞肺癌患者40例，予以洛铂35 mg/m2第1天，伊立替康 100 mg/m2 第1、8天，每21 d为一周期，每个周期结束复查CT评价疗效，观察其疗效及毒副反应。结果 完全缓解(CR)0例，部分缓解(PR)14例，疾病稳定(SD)12例，疾病进展(PD)14例，客观缓解率(ORR)35%，疾病控制率(DCR)65%，中位无进展生存期(PFS)4.2个月，中位生存期(OS)7.9个月，主要毒副反应为血液学毒性、恶心、呕吐及腹泻，全组无毒性相关死亡。结论 伊立替康联合洛铂可用于治疗复发广泛期小细胞肺癌，不良反应可以耐受。
【关键词】
伊立替康；洛铂；化疗；小细胞肺癌；复发
Clinical observation of Irinotecan and Lobaplatin treatment of advanced relapsed small cell lung cancer
JIANG Kan， HUANG Cheng， WU Biao，et al.Department of Medical Oncology, Fujian Provincial Tumor Hospital, Fujian Medical University Educational Hospital, Fuzhou 350014, China
【Abstract】 Objective
To observe the efficacy and toxicity ofchemotherapy combined Irinotecan with Lobaplatin in advanced relapsed small cell lung cancer(SCLC)patients. Methods A total of 40 advancedly relapsed SCLC patients received Lobaplatin 35 mg/m2 and Irinotecan100 mg/m2D1，8 Days by the intravenous administration with 21 days as a cycle. Efficacy was estimated by imaging every cycle. Results For a total of 40 patients, 14 patients was PR, 12 patients was SD, 14 patients was PD.The objective response rate(ORR)was 35%.The disease control rate(DCR)was 65%.The median progression free survival(PFS)was 4.2 months. The median overall survival(OS)was 7.9 months.The most commonly seen adverse events(AEs)were myelosuppression，nausea，vomit and diarrhea.There was no treatment-related death. Conclusion The chemotherapy combined Irinotecan with Lobaplatin is effective and safe in treating patients with SCLC after failure of the first-line chemotherapy.The adverse events are tolerated.
【Key words】
Irinotecan；Lobaplatin；chemotherapy；small cell lung cancer(SCLC); Relapsed
小细胞肺癌(small cell lung cancer，SCLC)占原发性肺癌的20%~25%，该类细胞具有特异性生物学行为，恶性程度高， 生长数度快，倍增时间短，分裂指数高，早期易出现远处广泛转移，被认为是一种全身性疾病，由于SCLC的以上生物学特点，化疗作为其首选治疗方法已经得到临床工作者的共识。SCLC对化疗高度敏感，足叶乙甙联合铂类方案化疗是广泛期小细胞肺癌目前最为常用的一线化疗方案，一线的化疗有效率为60%~80%，广泛期中位生存期9~11个月，但大多数患者会在数月内复发或疾病进展，且复发后大多耐药，目前尚无标准二线化疗方案[1] ......
您现在查看是摘要介绍页，详见PDF附件(1949KB，2页)。